DCM
ALNY icon

Dupont Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Dupont Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-14,399
Closed -$910K – 625
2014
Q2 		$910K Buy
14,399
+4,900
+52% +$291K 0.01% 513
2014
Q1 		$638K Sell
9,499
-4,690
-33% -$363K 0.01% 568
2013
Q4 		$913K Sell
14,189
-1,734
-11% -$103K 0.02% 511
2013
Q3 		$1.02M Sell
15,923
-39,269
-71% -$1.96M 0.02% 476
2013
Q2 		$1.71M Buy
+55,192
New +$1.47M 0.03% 400

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Dupont Capital Management's ALNY Position: Q3 2014 in Review

Dupont Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2014, closing a stake of 14,399 shares — an estimated $910K sold.

Dupont Capital Management first reported a position in ALNY in Q2 2013 and held it in 5 quarters. The position peaked at $1.71M in Q2 2013. 185 funds tracked by Wall St. Rank hold ALNY as of Q3 2014.

  • Dupont Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • Dupont Capital Management sold 14,399 Alnylam Pharmaceuticals shares in Q3 2014, an estimated $910K.
  • Dupont Capital Management first reported a position in Alnylam Pharmaceuticals in Q2 2013 and held it in 5 quarters.
  • Dupont Capital Management's Alnylam Pharmaceuticals position peaked at $1.71M in Q2 2013.
  • 185 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2014.

Based on Dupont Capital Management's 13F filing for Q3 2014, filed 3 Nov 2014.